mdi Consultants, IncThe Answer Might Surprise You.
One of the most common questions we have received from manufacturers, software developers, and startup founders this year is:
Is my product still considered a medical device by the FDA?”
The short answer is: maybe not—but don’t assume.
In 2026, the FDA continued refining its approach to certain low-risk health technologies, including general wellness products, clinical decision support (CDS) software, and some consumer health wearables. As a result, some products that previously raised regulatory concerns may now fall outside FDA device oversight, while others remain firmly regulated.
However, the biggest mistake we see companies make is assuming that because a product is low risk, digital, AI-enabled, or wellness-focused, it is automatically exempt from FDA requirements. That assumption can become very expensive.
If your product diagnoses, treats, mitigates, prevents, or monitors a disease or medical condition, drives a clinical decision, or makes medical claims, there is a strong possibility that it remains an FDA-regulated medical device.
On the other hand, if your product simply promotes general wellness, displays information without interpretation, or supports—but does not replace—a healthcare professional’s judgment, it may fall outside FDA medical device regulation.
The challenge is determining exactly where your product falls.
After nearly 50 years of helping companies navigate FDA requirements, I can tell you that the classification question is often far more important than the submission itself.
What changed in 2026?
Over the past year, the FDA has continued to emphasize innovation and has signaled its desire to regulate lower-risk technologies more efficiently.
This has resulted in a more refined approach to three primary categories:
1. General Wellness Products
These are products intended to promote a healthy lifestyle or maintain general health without making claims related to specific diseases or medical conditions.
Examples may include:
- Fitness trackers
- Activity monitors
- Sleep monitoring devices
- Stress management applications
- Wellness coaching platforms
As long as these products avoid disease-related claims and present minimal risk to users, they may not be regulated as medical devices.
2. Clinical Decision Support (CDS) Software
The FDA has continued to distinguish between software that:
- Assists healthcare professionals in making decisions, and
- Software that independently analyzes information and generates recommendations that clinicians cannot independently evaluate.
If a clinician can review the basis for the recommendation and independently reach the same conclusion, the software may qualify for reduced regulatory oversight.
However, software that effectively drives clinical decisions without transparent reasoning may still be regulated.
3. Consumer Health Wearables
Many wearable technologies continue to evolve rapidly.
Products that simply collect and display information may be subject to less FDA scrutiny than products that:
- Diagnose medical conditions
- Detect disease
- Recommend treatment
- Trigger clinical interventions
The key factor is often not the hardware itself—but rather what the product claims to do.
The Four Questions MDI Asks Every Client
When evaluating whether a product is still regulated as a medical device, I typically start with four simple questions:
If the answer is yes, the product is likely regulated by the FDA.
Displaying data is generally lower risk.
Interpreting data and providing medical conclusions often moves the product into medical device territory.
The more the user relies on the software’s output without independent review, the greater the likelihood of FDA oversight.
This is one of the most overlooked questions.
FDA classification is often determined as much by marketing claims as by the technology itself.
For example:
A mobile application that tracks blood pressure readings may be considered a wellness or monitoring tool.
The exact same application that claims to “detect hypertension” may be regulated as a medical device.
The technology did not change.
The claim did.
Why Marketing Claims Matter So Much
In our experience, companies often focus on product design while overlooking labeling, advertising, website content, social media posts, sales brochures, and investor presentations.
FDA reviews all of these materials when evaluating intended use.
We have seen companies unintentionally convert a low-risk product into a regulated medical device simply by adding statements such as:
- “Detects disease”
- “Improves treatment outcomes”
- “Identifies patients at risk”
- “Provides clinical recommendations”
- “Reduces symptoms of a medical condition”
A single claim can significantly alter the regulatory pathway.
That is why classification reviews should always include a review of marketing materials—not just technical specifications.
What Happens If You Guess Wrong?
The consequences can be substantial.
If You Assume…
Potential Consequences
“We’re exempt” when the product is actually regulated
Misbranding, import detention, import alerts, warning letters, FDA enforcement actions, product removal, and lost market opportunities
“We’re regulated” when the product may be exempt
Unnecessary testing, delayed product launch, excessive consulting costs, and months of avoidable regulatory work
Both mistakes are common.
Both are avoidable.
What about Products Already on the Market?
This is another area many manufacturers overlook.
Even if your product has already been commercialized, regulatory obligations can change over time.
We recommend reviewing your regulatory strategy whenever:
- New FDA guidance is issued
- Software functionality changes
- Artificial intelligence features are added
- Marketing claims are expanded
- New indications for use are introduced
- Labeling is revised
- Distribution expands into new markets
A product that was appropriately classified two years ago may require a different regulatory assessment today.
MDI Recommendation
Before spending money on testing, quality systems, FDA submissions, or product launches, make sure you understand whether your product is actually regulated as a medical device.
A classification assessment often takes less than an hour and can save months of work, significant expense, and potential regulatory problems.
At MDI Consultants, we have been helping manufacturers navigate FDA regulations since 1978. During that time, we have supported companies ranging from startups to multinational manufacturers and have prepared more than 5,000 FDA submissions across a wide range of medical technologies.
If you are uncertain whether your product remains an FDA-regulated device in 2026, now is the time to find out.
